QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
(deCODE Genetics and Dr. William J. Catalona have collaborated on genetic research to identify the risk factors for prostate cancer.) In September of this year, deCODE Genetics announced that a team of its scientists discovered four novel single-letter variations in…
T he digital rectal exam (DRE) should always be included as part of prostate cancer screening. It is an important predictor for prostate cancer, and in particular, aggressive prostate cancer. The DRE sometimes picks up cancers before a PSA test…
My Father passed away in 1980 from metastatic prostate cancer, only six months after he was diagnosed. Unfortunately, it was still a few years before Dr. William Catalona began directing the research efforts of the URF and before the wide…
One option now offered to men who are diagnosed with seemingly less aggressive prostate cancer is active surveillance or “watchful waiting.” The idea is that some patients won’t need treatment; their cancer will not progress and they can avoid surgery…
I n April of 2009, the American Urological Association (AUA) issued new clinical guidelines regarding early detection of prostate cancer and the PSA test. A summary follows: The AUA recommendation is: The PSA (prostate-specific antigen) test should be offered to…
When Mark Dugan was diagnosed with prostate cancer, shortly after his 55th birthday, he had a lot of people to tell and he wasn’t sure how to tell them. First were his wife, two adult children, two adult stepchildren, two…
(Dr. Catalona was a resource for this article. Courtesy of Globe and Mail, we are reprinting that portion of the article which relied on information from him.) One of the problems with active surveillance, Dr. Catalona said, is that there…
The European Randomized Study of Screening for Prostate Cancer (ERSPC) reported that men who were assigned to be screened had a 20% lower death rate from prostate cancer than men not assigned to be screened. However, screening carried a high…
In March 2009, the results of two long awaited trials were published in the New England Journal of Medicine.1,2 One said that screening with PSA reduced deaths from prostate cancer by up to 27% and the other claimed it didn’t…
At the end of 2008, the National Cancer Institute published its findings on the incidence of various cancers and cancer-caused deaths with encouraging news regarding most cancers and especially for prostate cancer. The media picked up the drop in incidence…
"*" indicates required fields
